A comparison of therapy continuation rates of different hormone replacement agents: a 9-month retrospective, longitudinal analysis of pharmacy claims among new users. Menopause (New York, N.Y.) [Menopause] Journal article | | Title | A comparison of therapy continuation rates of different hormone replacement agents: a 9-month retrospective, longitudinal analysis of pharmacy claims among new users. | | Author(s) | Simon JA, Wysocki S, Brandman J, Axelsen K | | Institution | Department of Obstetrics and Gynecology, George Washington University School of Medicine, Washington, DC, USA. | | Source | Menopause 2003 Jan-Feb; 10(1):37-44. | | MeSH | Adolescent
Adult
Age Factors
Aged
Cohort Studies
Comparative Study
Estrogen Replacement Therapy
Ethinyl Estradiol-Norgestrel Combination
Female
Humans
Insurance Claim Review
Insurance, Pharmaceutical Services
Longitudinal Studies
Male
Middle Aged
Odds Ratio
Patient Compliance
Physician's Practice Patterns
Research Support, Non-U.S. Gov't
Retrospective Studies
United States
| | Abstract | OBJECTIVE: To estimate the rate of therapy continuation among women using six different hormone replacement therapies (HRTs).
DESIGN: A retrospective, longitudinal analysis of pharmacy claims data was conducted for 7,120 women who were new users of six HRT regimens. Continuation rates of therapies were examined at the end of the 9-month period. In addition, the odds ratio of continuation for each product was determined using a logistic model, which controlled for the potential influence of a patient's age and a provider's age, gender, specialty, and geographical location.
RESULTS: Treatment continuation rates at the end of the 9-month period were significantly higher among patients prescribed oral 1 mg norethindrone acetate/5 microgram ethinyl estradiol (EE) (femhrt, Pfizer Inc, New York, NY, USA) compared with other HRT regimens. Patients prescribed 1 mg norethindrone acetate/5 microgram EE were 52% more likely to continue therapy compared with patients prescribed 0.625 mg conjugated equine estrogens/2.5 mg or 5 mg medroxyprogesterone acetate (Prempro, Wyeth, Madison, NJ, USA). Significantly higher rates of therapy continuation were seen in women aged 55 years or older, those who did not switch HRT during the analysis, those who received care in the central and northeast regions of the United States, and those who were seen by obstetricians/gynecologists (v primary care physicians) or female (v male) providers.
CONCLUSIONS: The higher rates of treatment continuation seen with newer continuous combined HRTs, such as 1 mg norethindrone acetate/5 microgram EE, may lead to improved long-term compliance and, therefore, better protection against osteoporosis in postmenopausal women. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 12544675 |
|
|
| |
Advertise on this site.
| | |
|
